IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer
FOLR1 is heterogeneously overexpressed in epithelial ovarian cancer. We examined the combined effects of the anti-FOLR1 antibody-drug conjugate (IMGN853) with other drugs, including topotecan, anti-VEGF-A antibody, and olaparib. These findings could contribute to the continued development of IMGN853 in the treatment of ovarian cancer.
Authors
- Anca Chelariu-Raicu (ORCID: https://orcid.org/0000-0003-2944-9488)
- Barrett C. Lawson (ORCID: https://orcid.org/0000-0003-2485-7087)
- Elaine Stur (ORCID: https://orcid.org/0000-0001-5962-0050)
- Yunfei Wen (ORCID: https://orcid.org/0000-0001-5313-1117)
- Pahul Hanjra (ORCID: https://orcid.org/0000-0002-7705-7967)
- Jinsong Liu (ORCID: https://orcid.org/0000-0002-3239-6658)
- Sujanitha Umamaheswaran (ORCID: https://orcid.org/0000-0002-3845-9373)
- Thanh Chung Vu (ORCID: https://orcid.org/0000-0002-8770-1269)
- Jerome Lin (ORCID: https://orcid.org/0000-0002-5424-9499)
- Anil K. Sood (ORCID: https://orcid.org/0000-0003-4242-1762)
- Yunah Han
- Min Hu (ORCID: https://orcid.org/0000-0002-5990-3816)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Davidson College (US)
- German Cancer Research Center (DE)
- LMU Klinikum (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0215
- Citations
- 3
- Primary Topic
- Autophagy in Disease and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 4.06